Laminin activates the p185(HER2) oncoprotein and mediates growth inhibition of breast carcinoma cells

British Journal of Cancer

Volumn 74, Issue 9, 1996, Pages 1427-1433

  Tagliabue, E ^a   Ardini, E ^a   Pellegrini, R ^a   Campiglio, M ^a   Bufalino, R ^a   Jeschke, M ^b   Groner, B ^c   Colnaghi, M I ^a   Menard S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Friedrich Miescher Institute Basle   (Switzerland)

^c TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Breast Cancer; Laminin; Oncoprotein

Indexed keywords

FIBRONECTIN; INTEGRIN; LAMININ; ONCOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR PROTEIN; TYROSINE;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR INTERACTION; ONCOGENE C ERB; PRECIPITATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; TISSUE SECTION; BIOSYNTHESIS; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DOWN REGULATION; DRUG EFFECT; FEMALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTO ONCOGENE;

BREAST NEOPLASMS; CELL DIVISION; DOWN-REGULATION; FEMALE; FIBRONECTINS; GENES, ERBB-2; HUMANS; LAMININ; NEOPLASM PROTEINS; PHOSPHORYLATION; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0029661840     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.560     Document Type: Article

References (49)

1. AKIYAMA T, SUDO C, OGAWARA M, TOYOSHIMA K AND YAMAMOTO T. (1986). The product of the c-erbB-2 gene; a 185Kd glycoprotein with tyrosine kinase activity. Science, 232, 1644 - 1646.
2. ARONHEIM A, ENGELBERG D, LI N, AL-ALAWI N, SCHLESSINGER J AND KARIN M. (1994). Membrane targeting of the nucleotide exchange factor sos is sufficient for activating the ras signaling pathway. Cell, 78, 949 - 961.
3. BACUS SS, STANCOVSKI I, HUBERMAN E, CHIN D, HURWITZ E, MILLS GB, ULLRICH A, SELA M AND YARDEN Y. (1992). Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res., 52, 2580 - 2589.
4. BEN-LEVY R, PATERSON HF, MARSHALL CJ AND YARDEN Y (1994), A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J., 13, 3302 3311.
5. BERCHUNCK A, KAMEL A, WHITAKER R, KERNS B, OLT G, KINNEY R, SOPER JT, DODGE R, CLARKE-PEARSON DL, MARKS P, MCKENZIE S, YIN S AND BAST RC, JR. (1990). Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50, 4087 - 4091.
6. HER2 oncoprotein and integrin α6β4 in Calu-3 lung carcinoma cells. J. Cell. Biochem., 55, 409 - 418.
7. CARRAWAY KL, III, SLIWKOWSKI MX, AKITA R, PLATKO JV, GUY PM, NUIJENS A, DIAMONTI AJ, VANDLEN RL, CANTLEY LC AND CERIONE RA. (1994). The erbB3 gene product is a receptor for heregulin. J. Biol. Chem., 269, 14303 - 14306.
8. CENTIS F, TAGLIABUE E, UPPUGUNDURI S, PELLEGRINI R, MARTIGNONE S, MASTROIANNI A, MÉNARD S AND COLNAGHI MI. (1992), p185 HER2/neu epitope mapping with murine monoclonal antibodies. Hybridoma, 11, 267 276.
9. CONNELLY PA AND STERN DF. (1990). The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. Proc. Natl Acad. Sci. USA, 87, 6054-6057.
10. COUSSENS L, YANG-FENG, TL, LIAO Y-C, CHEN E, GRAY A, MCGRATH J, SEEBURG PH, LIBERMANN FA, SCHLESSINGER J, FRANCKE U, LEVINSON A AND ULLRICH A. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230, 1132 - 1139.
11. DI FIORE, PP, PIERCE JH, KRAUS MH, SEGATTO O, KING CR AND AARONSON SA. (1987). erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 237, 178-182.
12. DOBASHI K, DAVIS JG, MIKAMI Y, FREEMAN JK, HAMURO J AND GREENE MI. (1991). Characterization of a neu/c-erbB-2 protein-specific activating factor. Proc. Natl Acad. Sci. USA, 88, 8582-8586.
13. GULLICK WJ. (1990). 4. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int. J. Cancer, 46, (Suppl. 5), 55 61.
14. erbB2. Science, 256, 1205 - 1210.
15. HUANG SS AND HUANG JS. (1992). Purification and characterization of the neu/erb B2 ligand-growth factor from bovine kidney. J. Biol. Chem., 267, 11508 - 11512.
16. HUDZIAK RM, LEWIS GD, WINGET M, FENDLY BM, SHEPARD HM AND ULLRICH A. (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9, 1165 - 1172.
17. HURWITZ E, STANCOVSKI I, SELA M AND YARDEN Y. (1995). Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl Acad. Sci. USA, 92, 3353-3357.
18. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50, 5184 - 5191.
19. KING CR, BORRELLO I, BELLOT F, COMOGLIO P AND SCHLESSINGER J. (1988). EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. EMBO J., 7, 1647 - 1651.
20. KITA YA, BARFF J, LUO Y, WEN D, BRANKOW D, HU S, LIU N, PRIGENT SA, GULLICK WJ AND NICOLSON M. (1994). NDF/heregulin stimulates the phosphorylation of Her3/erbB3. FEBS Lett., 349, 139 - 143.
21. 1 integrins. Proc. Natl Acad. Sci. USA, 88, 8392 - 8396.
22. KRAUS MH, FEDI P, STARKS V, MURARO R AND AARONSON SA. (1993). Demonstration of ligand-dependent signaling by the erhB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc. Natl Acad. Sci. USA, 90, 2900 - 2904.
23. LEE EC, LOTZ MM, STEELE GD, JR AND MERCURIO AM. (1992). The integrin α6β4 is a laminin receptor. J. Cell Biol., 117, 671 - 678.
24. LUCKOW AV AND SUMMERS MD. (1989). High level expression of nonfused foreign genes with autographa californica nuclear polyhydrosis virus expression vectors. Virology, 170, 31 - 39.
25. LUPU R, COLOMER R, ZUGMAIER G, SARUP J, SHEPARD M, SLAMON D AND LIPPMAN ME. (1990). Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185 erbB2. Science, 249, 1552 - 1555.
26. MARTIGNONE S, PELLEGRINI R, VILLA E, TANDON NN, MASTROIANNI A, TAGLIABUE E, MÉNARD S AND COLNAGHI MI, (1992). Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. Clin. Exp. Metast., 10, 379 - 386.
27. MATSUDA S, KADOWAKI Y, ICHINO M, AKIYAMA T, TOYOSHIMA K AND YAMAMOTO T. (1993). 17β-Estradiol mimics ligand activity of the c-erhB2 protooncogene product. Proc. Natl Acad. Sci. USA, 90, 10803 - 10807.
28. MCKENZIE SJ, MARKS PJ, LAM T, MORGAN J, PANICALI DL, TRIMPE KL AND CARNEY WP. (1989). Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene, 4, 543 - 548.
29. PANAYOTOU G, END P, AUMAILLEY M, TIMPL R AND ENGEL J. (1989). Domains of laminin with growth-factor activity. Cell, 56, 93 - 101.
30. PARHAM P, BARNSTABLE CJ AND BODMER WF. (1979). Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C antigens. J. Immunol., 123, 342 - 349.
31. PELES E, BACUS SS, KOSKI RA, LU HS, WEN D, OGDEN SG, BEN LEVY, R AND YARDEN Y. (1992). Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell, 69, 205 - 216.
32. PELLEGRINI R, CENTIS F, MARTIGNONE S, MASTROIANNI A, TAGLIABUE E, TOSI E, MÉNARD S AND COLNAGHI MI. (1991). Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site. Cancer Immunol. Immunother., 34, 37 - 42.
33. PELLEGRINI R, BAZZINI P, TOSI E, TAGLIABUE E, CONFORTI G, DEJANA E, MENARD S AND COLNAGHI MI. (1992). Production and characterization of two monoclonal antibodies directed against the integrin β1 chain. Tumori, 78, 1 - 4.
34. PELLEGRINI R, MARTIGNONE S, TAGLIABUE E, BELOTTI D, BUFALINO R, MÉNARD S AND COLNAGHI MI. (1995). Prognostic significance of laminin production in relation with its receptor expression in human breast carcinoma. Breast Cancer Res. Treat., 35, 195 - 199.
35. erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl Acad. Sci. USA, 90, 1746 - 1750.
36. PLOWMAN GD, GREEN JM, CULOUSCOU J-M, CARLTON GW, ROTHWELL VM AND BUCKLEY S. (1993/b). Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature, 366, 473-475.
37. RILKE F, COLNAGHI MI, CASCINELLI N, ANDREOLA S, BALDINI MT, BUFALINO R, DELLA PORTA G, MÉNARD S, PIEROTTI MA AND TESTORI A. (1991). Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int. J. Cancer., 49, 44 - 49.
38. c-neu density govern receptor interactions and tyrosine kinase activation. Proc. Natl Acad. Sci. USA, 91, 1711 1715.
39. SASAKI M AND YAMADA Y. (1987). The laminin b2 chain has a multidomain structure homologous to the b1 chain. J Biol. Chem., 262, 17111 - 17117.
40. SASAKI M, KATO S, KOHNO K, MARTIN GR AND YAMADA Y. (1987). Sequence of cDNA encoding the laminin b1 chain reveals a multidomain protein containing cysteine-rich repeats. Proc. Natl Acad. Sci. USA, 84, 935 - 939.
41. SLAMON DJ, GODOLPHIN W, JONES LA, HOLT JA, WONG SC, KEITH DE, LEVIN WJ, STUART SG, UDOVE J, ULLRICH A AND PRESS MF. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707 - 712.
42. SLIWKOWSKI MX, SCHAEFER G, AKITA RW, LOFGREN JA, FITZPATRICK VD, NUIJENS A, FENDLY BM, CERIONE RA, VANDLEN RL AND CARRAWAY KL, III. (1994). Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem., 269, 14661 - 14665.
43. STANCOVSKI I, HURWITZ E, LEITNER O, ULLRICH A, YARDEN Y AND SELA M. (1991). Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Natl Acad, Sci. USA, 88, 8691 - 8695.
44. HER2 and growth inhibition of cells with HER2/neu gene amplification. Int. J. Cancer, 47, 933 - 937.
45. TARAKHOVSKY A, ZAICHUK T, PRASSOLOV V AND BUTENKO ZA. (1991). A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages. Oncogene, 6, 2187 - 2196.
46. TZAHAR E, LEVKOWITZ G, KARUNAGARAN D, YI L, PELES E, LAVI S, CHANG D, LIU N, YAYON A, WEN D AND YARDEN Y. (1994). ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J. Biol. Chem., 269, 25226 - 25233.
47. WEN D, PELES E, CUPPLES R, SUGGS SV, BACUS SS, LUO Y, TRAIL G, HU S, SILBIGER SM, BEN LEVY R, KOSKI RA, LU HS AND YARDEN Y. (1992). Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell, 69, 559 - 572.
48. YARDEN Y AND WEINBERG RA. (1989). Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc. Natl Acad. Sci. USA, 86, 3179 - 3183.
49. ZSCHIESCHE W, SCHÖNBORN I, MINGUILLON C AND SPITZER E. (1994). Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer. Cancer Lett., 81, 89 - 94.